• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Vimpat (lacosamide)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Vimpat (lacosamide)

  • Profile

Profile

Contact Information

Website: http://www.vimpat.com/

Currently Enrolling Trials

    Show More

    General Information

     

    Vimpat tablets are specifically indicated as adjunctive therapy in the treatment of partial-onset seizures in patients with epilepsy ages 17 years and older. Vimpat injection for intravenous use is indicated as adjunctive therapy in the treatment of partial-onset seizures in patients with epilepsy ages 17 years and older when oral administration is temporarily not feasible.

     

    Mechanism of Action

    Vimpat is an orally available anticonvulsant. It selectively enhances slow inactivation of sodium channels and interacts with the neuroplasticity-relevant target collapsin-response mediator protein-2 (CRMP-2).

    Side Effects

    Adverse events associated with the use of Vimpat may include, but are not limited to, the following:

    • Dizziness
    • Nausea
    • Diplopia
    • Vision blurred
    • Vomiting
    • Fatigue
    • Ataxia

    Dosing/Administration

    Vimpat is supplied as a tablet designed for oral administration or as a solution designed for intravenous administration. The recommended initial dose is 50 mg twice daily (100 mg per day). Vimpat can be increased at weekly intervals by 100 mg/day given as two divided doses up to the recommended maintenance dose of 200 to 400 mg/day.

    Switching from oral to intravenous dosing
    The initial total daily intravenous dosage of Vimpat should be equivalent to the total daily dosage and frequency of oral Vimpat and should be infused intravenously over a period of 30 to 60 minutes.

    Switching from intravenous to oral dosing
    At the end of the intravenous treatment period, the patient may be switched to Vimpat oral administration at the equivalent daily dosage and frequency of the intravenous administration.

    Clinical Trial Results

    FDA Approval
    The FDA approval of Vimpat was based on the results of three clinical trials. These 12-week, randomized, double-blind, placebo-controlled, multicenter trials enrolled subjects with partial-onset seizures with or without secondary generalization and who were not adequately controlled with one to three concomitant AEDs. Study 1 compared doses of Vimpat 200 , 400 and 600 mg/day with placebo. Study 2 compared doses of Vimpat 400 and 600 mg/day with placebo. Study 3 compared doses of Vimpat 200 and 400 mg/day with placebo. Following an eight-week baseline phase to establish baseline seizure frequency prior to randomization, subjects were randomized and titrated to the randomized dose. During the titration phase in all three trials, treatment was initiated at 100 mg/day (50 mg given twice daily) and increased in weekly increments of 100 mg/day to the target dose. The titration phase lasted six weeks in Study 1 and Study 2 and four weeks in Study 3. In all three trials, the titration phase was followed by a maintenance phase that lasted 12 weeks. The primary end point was reduction in 28-day seizure frequency (baseline to maintenance phase) as compared to the placebo group. A statistically significant effect was observed with Vimpat treatment at doses of 200 mg/day (Study 3), 400 mg/day (Studies 1, 2 and 3), and 600 mg/day (Studies 1 and 2).

     

     

    Approval Date: 2008-10-01
    Company Name: Schwarz Pharma
    Back to Listings

    Upcoming Events

    • 16Feb

      Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

    • 21May

      WCG MAGI Clinical Research Conference – 2023 East

    Featured Products

    • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

      Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    Featured Stories

    • Revamp-360x240.png

      Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

    • AskTheExpertsGreen-360x240.png

      Ask the Experts: Managing Investigational Products

    • SurveywBlueBackground-360x240.png

      Survey Outlines Site Challenges, Successes on Diversity

    • PatientCentricity-360x240.png

      Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing